The populations of Th1 and Th17 were reduced in both the controls and MS patients, while memory CD8+ T populations were increased and LAP+ Tregs were decreased exclusively on MS patients and controls, respectively. The gene discussed is CD8A; the disease is myeloid sarcoma.